These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 22395256)

  • 1. Pegloticase: a novel agent for treatment-refractory gout.
    Shannon JA; Cole SW
    Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
    Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
    JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
    Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
    Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
    Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
    J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
    Biggers K; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
    Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
    J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
    Strand V; Khanna D; Singh JA; Forsythe A; Edwards NL
    J Rheumatol; 2012 Jul; 39(7):1450-7. PubMed ID: 22660805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegloticase and the patient with treatment-failure gout.
    Dave AJ; Kelly VM; Krishnan E
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.
    Hershfield MS; Ganson NJ; Kelly SJ; Scarlett EL; Jaggers DA; Sundy JS
    Arthritis Res Ther; 2014 Mar; 16(2):R63. PubMed ID: 24602182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegloticase: in treatment-refractory chronic gout.
    Lyseng-Williamson KA
    Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
    Becker MA; Baraf HS; Yood RA; Dillon A; Vázquez-Mellado J; Ottery FD; Khanna D; Sundy JS
    Ann Rheum Dis; 2013 Sep; 72(9):1469-74. PubMed ID: 23144450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegloticase. An excessively dangerous and inadequately evaluated hypouricaemic drug.
    Prescrire Int; 2014 Jul; 23(151):173-6. PubMed ID: 25162087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.
    Bleyer AJ; Wright D; Alcorn H
    Clin Nephrol; 2015 May; 83(5):286-92. PubMed ID: 25816806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
    Khanna PP; Khanna D; Cutter G; Foster J; Melnick J; Jaafar S; Biggers S; Rahman AKMF; Kuo HC; Feese M; Kivitz A; King C; Shergy W; Kent J; Peloso PM; Danila MI; Saag KG
    Arthritis Rheumatol; 2021 Aug; 73(8):1523-1532. PubMed ID: 33750034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegloticase (krystexxa) for treatment of refractory gout.
    Med Lett Drugs Ther; 2011 Feb; 53(1357):9-10. PubMed ID: 21304442
    [No Abstract]   [Full Text] [Related]  

  • 18. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
    Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
    Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
    Baraf HSB; Khanna PP; Kivitz AJ; Strand V; Choi HK; Terkeltaub R; Dalbeth N; DeHaan W; Azeem R; Traber PG; Keenan RT
    Rheumatology (Oxford); 2024 Apr; 63(4):1058-1067. PubMed ID: 37449908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.